Filibuvir

Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily.

单词	Filibuvir
释义	Filibuvir 英语百科 Filibuvir Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily.
随便看	creation data creation date creation design creation facilities program creation facility program creationism creationism, theory of special creation creationist creationless creation method creation mode creation model Creation myth Creation of aortocarotid shunt Creation of aortocarotid vascular bypass Creation of aortoceliac shunt Creation of aortofemoral shunt Creation of aortofemoral vascular bypass Creation of aortoiliac shunt Creation of aortomesenteric shunt Creation of aortorenal shunt Creation of aortorenal vascular bypass Creation of aortosubclavian shunt creation of a parent plant Creation of arterial bypass with synthetic graft